Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marc Simon, MD
University of California, San Francisco
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona
Tucson, Arizona, United States
- Harbor-Ucla Medical Center
Torrance, California, United States
- Indiana University
Indianapolis, Indiana, United States
- National Institutes of Health
Bethesda, Maryland, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Inova Fairfax Hospital
Falls Church, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Apr 2017
- Primary completion
- 16 Aug 2022
- Completion
- 16 Sept 2022
- Last update posted
- 25 Nov 2024
- Registered enrollment
- 15
- Registry id
- NCT02587325
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.